---
title: "HWHG: Levonorgestrel tablets have obtained a drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257494695.md"
description: "HWHG announced that its holding subsidiary Jiulong HWHG has obtained the drug registration certificate for Levonorgestrel Tablets issued by the National Medical Products Administration. This approval enables the company to sell the drug in the domestic market, enriches its product line, and is expected to have a positive impact on the company. Jiulong HWHG will arrange the production and launch of the drug according to market demand"
datetime: "2025-09-16T08:19:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257494695.md)
  - [en](https://longbridge.com/en/news/257494695.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257494695.md)
generator: "portal-rs"
---

# HWHG: Levonorgestrel tablets have obtained a drug registration certificate

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its holding subsidiary, Wuhan Jiulong HWHG Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiulong HWHG," which is 100% owned by the company's holding subsidiary Hubei Gedian HWHG Pharmaceutical Co., Ltd.), recently received the "Drug Registration Certificate" for Levonorgestrel Tablets approved and issued by the National Medical Products Administration.

The approval of Levonorgestrel Tablets marks the company's qualification to sell this drug in the domestic market. This product further enriches the company's product line, and its market launch will have a positive impact on the company. Jiulong HWHG will arrange for the production and market launch of Levonorgestrel Tablets based on market demand

### Related Stocks

- [600079.CN](https://longbridge.com/en/quote/600079.CN.md)

## Related News & Research

- [Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection](https://longbridge.com/en/news/295637927.md)
- [YUSHU TECHNOLOGY Founder Wang Xingxing Says Humanoid Robots' 'ChatGPT Moment' May Still Be a Decade Away; Nomura Initiates Coverage with Buy Rating](https://longbridge.com/en/news/296462640.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [China's Daqo New Energy Q2 revenue falls on weak demand](https://longbridge.com/en/news/296476125.md)
- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**